SCHEMBL30142384

SCHEMBL30142384

CC(C)CNC(=O)c1n[nH]c2c(F)cccc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 10/20 0.51
▸ GSK3B P49841 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ KMT2A Q03164 3/20 0.44
▸ GAA P10253 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ WNT1 P04628 3/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ALPL P05186 1/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MLYCD O95822 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30142289 0.86 DYRK1A (0.41) DYRK1AGSK3BKDM4EALDH1A1HSD17B10
SCHEMBL30142240 0.85 SMN1; SMN2 (0.44) DYRK1AKDM4EALDH1A1KMT2AGAA
SCHEMBL30142262 0.85 KDM4E (0.43) DYRK1AKDM4EALDH1A1HSD17B10WNT1
SCHEMBL30142404 0.85 KDM4E (0.43) DYRK1AKDM4EALDH1A1HSD17B10WNT1
SCHEMBL30142357 0.83 SMN1; SMN2 (0.60) DYRK1AKDM4EALDH1A1KMT2AWNT1
SCHEMBL30142319 0.82 RAB9A (0.48) DYRK1AKDM4EALDH1A1KMT2AGAA
SCHEMBL30142285 0.81 YTHDC1 (0.59) DYRK1AGSK3BKDM4EALDH1A1GAA
SCHEMBL30142246 0.80 WNT1 (0.62) DYRK1AKDM4EALDH1A1WNT1SMN1; SMN2
SCHEMBL30142244 0.80 WNT1 (0.49) DYRK1AKDM4EALDH1A1KMT2AGAA
SCHEMBL30142245 0.80 WNT1 (0.49) DYRK1AKDM4EALDH1A1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388964-A1 (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS HIBERCELL, INC. 2022-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388964-A1 (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS EIF2AK4, GCN1, GNAI2 DYRK1A 3529/4885GSK3B 2570/4885KDM4E 2876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback